BioAge Labs, Inc. (NASDAQ:BIOA) Short Interest Down 16.3% in January

BioAge Labs, Inc. (NASDAQ:BIOA) was the recipient of a large decrease in short interest in the month of January. As of January 30th, there was short interest totaling 909,129 shares, a decrease of 16.3% from the January 15th total of 1,085,882 shares. Currently, 3.2% of the shares of the company are sold short. Based on an average daily volume of 919,863 shares, the days-to-cover ratio is currently 1.0 days. Based on an average daily volume of 919,863 shares, the days-to-cover ratio is currently 1.0 days. Currently, 3.2% of the shares of the company are sold short.

BioAge Labs Trading Down 1.9%

Shares of BIOA opened at $19.57 on Monday. BioAge Labs has a 12-month low of $2.88 and a 12-month high of $24.00. The company has a market cap of $701.58 million, a PE ratio of -12.88 and a beta of 1.40. The stock has a 50-day moving average price of $16.62 and a 200-day moving average price of $9.83.

Insider Activity

In other BioAge Labs news, insider Paul D. Rubin sold 7,433 shares of the firm’s stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $18.75, for a total value of $139,368.75. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Dov A. Md Goldstein sold 27,000 shares of the company’s stock in a transaction on Tuesday, January 13th. The shares were sold at an average price of $19.70, for a total value of $531,900.00. Following the transaction, the chief financial officer directly owned 22,408 shares in the company, valued at $441,437.60. This represents a 54.65% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 354,437 shares of company stock valued at $5,813,228 in the last ninety days. 20.82% of the stock is currently owned by insiders.

Hedge Funds Weigh In On BioAge Labs

A number of institutional investors have recently made changes to their positions in BIOA. Vanguard Group Inc. increased its stake in shares of BioAge Labs by 6.0% in the third quarter. Vanguard Group Inc. now owns 1,651,247 shares of the company’s stock worth $9,709,000 after buying an additional 93,694 shares during the period. Geode Capital Management LLC grew its holdings in BioAge Labs by 5.1% in the 4th quarter. Geode Capital Management LLC now owns 591,377 shares of the company’s stock worth $7,826,000 after acquiring an additional 28,646 shares during the last quarter. State Street Corp increased its position in shares of BioAge Labs by 113.4% in the fourth quarter. State Street Corp now owns 422,846 shares of the company’s stock valued at $5,594,000 after acquiring an additional 224,735 shares during the period. Jacobs Levy Equity Management Inc. increased its position in shares of BioAge Labs by 56.8% in the fourth quarter. Jacobs Levy Equity Management Inc. now owns 334,126 shares of the company’s stock valued at $4,420,000 after acquiring an additional 121,038 shares during the period. Finally, Millennium Management LLC raised its stake in shares of BioAge Labs by 749.8% during the third quarter. Millennium Management LLC now owns 306,552 shares of the company’s stock valued at $1,803,000 after acquiring an additional 270,479 shares during the last quarter.

Analysts Set New Price Targets

Several analysts have recently issued reports on BIOA shares. Piper Sandler assumed coverage on shares of BioAge Labs in a research report on Tuesday, January 27th. They issued an “overweight” rating on the stock. Citigroup raised their price target on BioAge Labs from $10.00 to $15.00 and gave the stock a “buy” rating in a report on Wednesday, October 29th. Morgan Stanley set a $23.00 price target on BioAge Labs in a research report on Wednesday, February 4th. Weiss Ratings reissued a “sell (d-)” rating on shares of BioAge Labs in a report on Tuesday, January 27th. Finally, Wall Street Zen upgraded BioAge Labs from a “sell” rating to a “hold” rating in a research note on Tuesday, February 3rd. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $19.00.

BioAge Labs Company Profile

BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.